Alembic Pharmaceuticals informs about press release

02 Nov 2022 Evaluate

Alembic Pharmaceuticals has informed the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Mesalamine Extended-Release Capsules USP, 0.375 g. In this regard, the company has enclosed a press release.

The above information is a part of company’s filings submitted to BSE.

Alembic Pharma Share Price

773.55 10.65 (1.40%)
23-Feb-2026 15:40 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1733.75
Dr. Reddys Lab 1303.95
Cipla 1326.10
Zydus Lifesciences 908.85
Lupin 2250.55
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×